Found 375 articles
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
Alnylam Pharmaceuticals, Inc. today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with polyneuropathy.
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, Sept. 14 at 9:30 a.m. PT / 12:30 p.m. ET.
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
Alnylam Pharmaceuticals, Inc. today announced additional positive results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisiran
Vir Biotechnology, Inc. announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, Sept. 13, at 4:00 a.m. PT / 7:00 a.m. ET.
The trial will enroll about 4,000 people worldwide to confirm the drug's safety and immunogenicity profiles.
Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia– First monoclonal antibody authorized in Australia –
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product, sotrovimab, developed in partnership with GlaxoSmithKline (GSK).
WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Company", together with its subsidiaries "the Group", stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the six months, ending on June 30, 2021.
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
Alnylam Pharmaceuticals, Inc. announced today that it has achieved full patient enrollment in its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of cardiomyopathy in patients with transthyretin-mediated (ATTR) amyloidosis.
Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, reported financial results for the second quarter ended June 30, 2021 and provided a review of recent business and portfolio highlights.
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
Alnylam Pharmaceuticals, Inc. today reported its consolidated financial results for the second quarter ended June 30, 2021 and reviewed recent business highlights.
Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
Allogene Therapeutics, Inc. today announced the appointment of Elizabeth (Liz) Barrett and Vicki Sato, Ph.D. to the company’s Board of Directors.
Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and PeptiDream, Inc. (Tokyo Stock Exchange: 4587), announced today a license and collaboration agreement to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver.
Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced positive topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 associated with progressive decline in renal function.
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, an investigational single dose SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19.
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021
Vir Biotechnology, Inc. announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021.
7/19/2021It was a moderately busy mid-summer week for clinical trial news. Here’s a look.
Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 MARCH trial evaluating VIR-2218 together with VIR-3434 for the treatment of patients with chronic hepatitis B virus (HBV) infection.
Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced initiation of KARDIA-1, a global Phase 2 study evaluating the efficacy and safety of zilebesiran, an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen in development for the treatment of hypertension.
ImmunoScape Expands its Executive and Scientific Teams to Extend Use of its Deep Immunomics Platform into Drug Discovery
ImmunoScape today announced it has made three strategic additions to its global team to expand the use of its innovative technology platform for drug discovery.